Dec 1, 2021
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...
2,922
Dec 18, 2019
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...
1,084
Dec 31, 2018
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...
811
Dec 19, 2018
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
KarMMa-2 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk...
520
Dec 8, 2018
NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
CANOVA TRIAL t(11;14)-positive Relapsed or Refractory Multiple Myeloma. A Study of Venetoclax and Dexamethasone Compared With...
325
Dec 24, 2016
NCT01564537: Phase 3 - TOURMALINE-MM1 - Oral Ixazomib + Len/Dex Vs Placebo + Len/Dex RRMM
TOURMALINE-MM1 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and...
326
Dec 18, 2015
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
STOMP Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP) This study will independently assess the efficacy and safety...
445
Dec 10, 2015
NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas,...
176
Dec 6, 2013
NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of Carfilzomib (CFZ) in...
204
Dec 16, 2011
NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
NCT01464034: Phase 1/2: A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or...
148
Dec 11, 2010
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NDMM - DFCI 10-106 DETERMINATION Trial Delayed vs Early Transplant with Revlimid Maintenance and Anti-Myeloma Triple Therapy DFCI 10-106...
1,132